{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:51:49Z","timestamp":1791337909807,"version":"4.3.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08571-7","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:03:56Z","timestamp":1783767836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic and functional analysis including repetitive antigen stimulation provides a more accurate assessment for CAR-T cell product quality and long-term functionality"],"prefix":"10.1186","volume":"24","author":[{"given":"Beatriz","family":"Guijarro-Albaladejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Sierro-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Carrasco-Brocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Hern\u00e1ndez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"de la Rosa-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Mu\u00f1oz-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Bejarano-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Ma\u00f1\u00e9-Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Alcalde-Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Rodr\u00edguez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Escamilla-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Lara-Chica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Aguirre-Portol\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Gal\u00e1n-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Escrib\u00e0-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Espa\u00f1ol-Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Briones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fern\u00e1ndez-de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-9860","authenticated-orcid":false,"given":"Estefan\u00eda","family":"Garc\u00eda-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"8571_CR1","doi-asserted-by":"publisher","unstructured":"Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, et al. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024;11(3):e216\u201327. https:\/\/doi.org\/10.1016\/S2352-3026(24)00005-X.","DOI":"10.1016\/S2352-3026(24)00005-X"},{"issue":"8","key":"8571_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"issue":"4","key":"8571_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2303379.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"8571_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1182\/blood-2023-178798","volume":"142","author":"R Mina","year":"2023","unstructured":"Mina R, Mylin AK, Yokoyama H, Magen H, Alsdorf W, Minnema MC, et al. Patient-reported outcomes in the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel vs standard of care in patients with lenalidomide-refractory multiple myeloma after 1\u20133 lines of therapy. Blood. 2023;142(Supplement 1):1063. https:\/\/doi.org\/10.1182\/blood-2023-178798.","journal-title":"Blood"},{"issue":"3","key":"8571_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141(3):219\u201330. https:\/\/doi.org\/10.1182\/blood.2022015526.","journal-title":"Blood"},{"issue":"1","key":"8571_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z, Chyra Z, Kotulov\u00e1 J, Celichowski P, Mih\u00e1lyov\u00e1 J, Charv\u00e1tov\u00e1 S, et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 2024;14(1):1\u201310. https:\/\/doi.org\/10.1038\/s41408-024-01193-6.","journal-title":"Blood Cancer J"},{"issue":"1","key":"8571_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cyto.b.21985","volume":"100","author":"G Sarikonda","year":"2021","unstructured":"Sarikonda G, Mathieu M, Natalia M, Pahuja A, Xue Q, Pierog PL, et al. Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses. Cytometry Part B Clin. 2021;100(1):79\u201391. https:\/\/doi.org\/10.1002\/cyto.b.21985.","journal-title":"Cytometry Part B Clin"},{"key":"8571_CR8","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129:2210\u201321. https:\/\/doi.org\/10.1172\/JCI126397.","journal-title":"J Clin Invest"},{"issue":"9","key":"8571_CR9","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s43018-024-00763-8","volume":"5","author":"M Rade","year":"2024","unstructured":"Rade M, Grieb N, Weiss R, Sia J, Fischer L, Born P, et al. Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma. Nat Cancer. 2024;5(9):1318\u201333. https:\/\/doi.org\/10.1038\/s43018-024-00763-8.","journal-title":"Nat Cancer"},{"issue":"9","key":"8571_CR10","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286\u201394. https:\/\/doi.org\/10.1038\/s41591-023-02496-0.","journal-title":"Nat Med"},{"issue":"5","key":"8571_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371. https:\/\/doi.org\/10.1038\/s41591-018-0010-1.","journal-title":"Nat Med"},{"key":"8571_CR12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI125423","volume":"129","author":"OC Finney","year":"2019","unstructured":"Finney OC, Brakke H, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019;129:2123\u201332. https:\/\/doi.org\/10.1172\/JCI125423.","journal-title":"J Clin Invest"},{"issue":"8","key":"8571_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","volume":"132","author":"J Rossi","year":"2018","unstructured":"Rossi J, Paczkowski P, Shen YW, Morse K, Flynn B, Kaiser A, et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018;132(8):804\u201314. https:\/\/doi.org\/10.1182\/blood-2018-01-828343.","journal-title":"Blood"},{"issue":"12","key":"8571_CR14","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26(12):1878\u201387. https:\/\/doi.org\/10.1038\/s41591-020-1061-7.","journal-title":"Nat Med"},{"key":"8571_CR15","doi-asserted-by":"publisher","unstructured":"Sierro-Mart\u00ednez B, Escamilla-G\u00f3mez V, P\u00e9rez-Ortega L, Guijarro-Albaladejo B, Hern\u00e1ndez-D\u00edaz P, de la Rosa-Garrido M, et al. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features. Cell Oncol (Dordr). 2024. https:\/\/doi.org\/10.1007\/s13402-024-00984-0.","DOI":"10.1007\/s13402-024-00984-0"},{"issue":"10","key":"8571_CR16","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145\u201354. https:\/\/doi.org\/10.1038\/s41591-022-01969-y.","journal-title":"Nat Med"},{"key":"8571_CR17","doi-asserted-by":"publisher","unstructured":"Salter AI, Ivey RG, Kennedy JJ, Voillet V, Rajan A, Alderman EJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018;11(544):eaat6753. https:\/\/doi.org\/10.1126\/scisignal.aat6753.","DOI":"10.1126\/scisignal.aat6753"},{"issue":"12","key":"8571_CR18","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1016\/j.ymthe.2020.07.023","volume":"28","author":"AC Boroughs","year":"2020","unstructured":"Boroughs AC, Larson RC, Marjanovic ND, Gosik K, Castano AP, Porter CBM, et al. A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq. Mol Ther. 2020;28(12):2577\u201392. https:\/\/doi.org\/10.1016\/j.ymthe.2020.07.023.","journal-title":"Mol Ther"},{"issue":"6","key":"8571_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390. https:\/\/doi.org\/10.1038\/nm.3838.","journal-title":"Nat Med"},{"issue":"2","key":"8571_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380\u201390. https:\/\/doi.org\/10.1016\/j.immuni.2016.01.021.","journal-title":"Immunity"},{"key":"8571_CR21","doi-asserted-by":"publisher","first-page":"105872","DOI":"10.1016\/j.ebiom.2025.105872","volume":"118","author":"B Gonz\u00e1lez-Mart\u00ednez","year":"2025","unstructured":"Gonz\u00e1lez-Mart\u00ednez B, Gal\u00e1n-G\u00f3mez V, Navarro-Zapata A, Mirones-Aguilar I, Cobo M, Pernas-S\u00e1nchez A, et al. Tandem CD19\/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r\/r B-ALL. EBioMedicine. 2025;118:105872. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105872.","journal-title":"EBioMedicine"},{"key":"8571_CR22","doi-asserted-by":"publisher","first-page":"1152498","DOI":"10.3389\/fimmu.2023.1152498","volume":"14","author":"CB Garc\u00eda-Calder\u00f3n","year":"2023","unstructured":"Garc\u00eda-Calder\u00f3n CB, Sierro-Mart\u00ednez B, Garc\u00eda-Guerrero E, Sanoja-Flores L, Mu\u00f1oz-Garc\u00eda R, Ruiz-Maldonado V, et al. Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. Front Immunol. 2023;14:1152498. https:\/\/doi.org\/10.3389\/fimmu.2023.1152498.","journal-title":"Front Immunol"},{"key":"8571_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jim.2004.11.021","volume":"297","author":"CE Brown","year":"2005","unstructured":"Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S, et al. Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods. 2005;297:39\u201352. https:\/\/doi.org\/10.1016\/j.jim.2004.11.021.","journal-title":"J Immunol Methods"},{"key":"8571_CR24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/blood-2024-210129","volume":"144","author":"A Carolina","year":"2024","unstructured":"Carolina A, Gonzalez C, Escrib\u00e0-Garcia L, Ujald\u00f3n-Mir\u00f3 C, Pujol Fern\u00e1ndez P, Montserrat-Torres R, et al. HSP-CAR30, an academic memory-enriched CART30, for the treatment of relapsed or refractory Hodgkin lymphoma and CD30+ T cell lymphoma: clinical results of a phase I\/II trial. Blood. 2024;144:920. https:\/\/doi.org\/10.1182\/blood-2024-210129.","journal-title":"Blood"},{"key":"8571_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","volume":"18","author":"DF Stroncek","year":"2016","unstructured":"Stroncek DF, Ren J, Lee DW, Tran M, Frodigh SE, Sabatino M, et al. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. Cytotherapy. 2016;18:893\u2013901. https:\/\/doi.org\/10.1016\/j.jcyt.2016.04.003.","journal-title":"Cytotherapy"},{"key":"8571_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3324\/haematol.2022.280805","volume":"108","author":"M Kwon","year":"2023","unstructured":"Kwon M, Iacoboni G, Reguera JL, L\u00f3pez Corral L, Morales RH, Ortiz-Maldonado V, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023;108:110\u201321. https:\/\/doi.org\/10.3324\/haematol.2022.280805.","journal-title":"Haematologica"},{"key":"8571_CR27","doi-asserted-by":"publisher","first-page":"100035","DOI":"10.1016\/j.adcanc.2022.100035","volume":"4","author":"U Ahmad","year":"2022","unstructured":"Ahmad U, Khan Z, Ualiyeva D, Amissah OB, Noor Z, Khan A, et al. Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; a comprehensive review. Adv Cancer Biol - Metastasis. 2022;4:100035. https:\/\/doi.org\/10.1016\/j.adcanc.2022.100035.","journal-title":"Adv Cancer Biol - Metastasis"},{"issue":"1","key":"8571_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-023-04372-4","volume":"21","author":"R Smith","year":"2023","unstructured":"Smith R, Shen R. Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality. J Transl Med. 2023;21(1):1\u201310. https:\/\/doi.org\/10.1186\/s12967-023-04372-4.","journal-title":"J Transl Med"},{"key":"8571_CR29","doi-asserted-by":"publisher","first-page":"947648","DOI":"10.3389\/fimmu.2022.947648","volume":"13","author":"CRF Silveira","year":"2022","unstructured":"Silveira CRF, Corveloni AC, Caruso SR, Mac\u00eado NA, Brussolo NM, Haddad F, et al. Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications. Front Immunol. 2022;13:947648. https:\/\/doi.org\/10.3389\/fimmu.2022.947648.","journal-title":"Front Immunol"},{"issue":"4","key":"8571_CR30","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ymthe.2018.01.022","volume":"26","author":"Z Cheng","year":"2018","unstructured":"Cheng Z, Wei R, Ma Q, Shi L, He F, Shi Z, et al. In vivo expansion and antitumor activity of coinfused CD28- and 4-1BB-engineered CAR-T cells in patients with B cell leukemia. Mol Ther. 2018;26(4):976\u201385. https:\/\/doi.org\/10.1016\/j.ymthe.2018.01.022.","journal-title":"Mol Ther"},{"key":"8571_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","volume":"15","author":"Z Ying","year":"2019","unstructured":"Ying Z, He T, Wang X, Zheng W, Lin N, Tu M, et al. Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin\u2019s lymphoma. Mol Ther - Oncolytics. 2019;15:60\u201368. https:\/\/doi.org\/10.1016\/j.omto.2019.08.002.","journal-title":"Mol Ther - Oncolytics"},{"key":"8571_CR32","doi-asserted-by":"publisher","unstructured":"Ramello MC, Benza\u00efd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, et al. An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci Signal. 2019;12:eaap9777. https:\/\/doi.org\/10.1126\/scisignal.aap9777.","DOI":"10.1126\/scisignal.aap9777"},{"issue":"4","key":"8571_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415\u201328. https:\/\/doi.org\/10.1016\/j.ccell.2015.09.004.","journal-title":"Cancer Cell"},{"key":"8571_CR34","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol. 2023;14:1101495. https:\/\/doi.org\/10.3389\/fimmu.2023.1101495.","journal-title":"Front Immunol"},{"issue":"18","key":"8571_CR35","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1817226.","journal-title":"N Engl J Med"},{"issue":"7251","key":"8571_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature08097","volume":"460","author":"EL Pearce","year":"2009","unstructured":"Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009;460(7251):103\u201307. https:\/\/doi.org\/10.1038\/nature08097.","journal-title":"Nature"},{"key":"8571_CR37","doi-asserted-by":"publisher","first-page":"1186383","DOI":"10.3389\/fimmu.2023.1186383","volume":"14","author":"W Li","year":"2023","unstructured":"Li W, Pan X, Chen L, Cui H, Mo S, Pan Y, et al. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy. Front Immunol. 2023;14:1186383. https:\/\/doi.org\/10.3389\/fimmu.2023.1186383.","journal-title":"Front Immunol"},{"key":"8571_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2022.01.006","volume":"529","author":"L Shen","year":"2022","unstructured":"Shen L, Xiao Y, Tian J, Lu Z. Remodeling metabolic fitness: strategies for improving the efficacy of chimeric antigen receptor T cell therapy. Cancer Lett. 2022;529:139\u201352. https:\/\/doi.org\/10.1016\/j.canlet.2022.01.006.","journal-title":"Cancer Lett"},{"issue":"21","key":"8571_CR39","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.3390\/cancers14215442","volume":"14","author":"J Rial Saborido","year":"2022","unstructured":"Rial Saborido J, V\u00f6lkl S, Aigner M, Mackensen A, Mougiakakos D. Role of CAR T cell metabolism for therapeutic efficacy. Cancers (Basel). 2022;14(21):5442. https:\/\/doi.org\/10.3390\/cancers14215442.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"8571_CR40","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nm.1982","volume":"15","author":"L Gattinoni","year":"2009","unstructured":"Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15(7):808\u201313. https:\/\/doi.org\/10.1038\/nm.1982.","journal-title":"Nat Med"},{"key":"8571_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cells10010014","volume":"10","author":"M Pellegrino","year":"2021","unstructured":"Pellegrino M, Del Bufalo F, De Angelis B, Quintarelli C, Caruana I, de Billy E. Manipulating the metabolism to improve the efficacy of CAR T-cell immunotherapy. Cells. 2021;10:14. https:\/\/doi.org\/10.3390\/cells10010014.","journal-title":"Cells"},{"issue":"13","key":"8571_CR42","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","volume":"8","author":"G Ledergor","year":"2024","unstructured":"Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, et al. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2024;8(13):3562\u201375. https:\/\/doi.org\/10.1182\/bloodadvances.2023012416.","journal-title":"Blood Adv"},{"key":"8571_CR43","doi-asserted-by":"publisher","unstructured":"Dimeloe S, Gubser P, Loeliger J, Frick C, Develioglu L, Fischer M, et al. Tumor-derived TGF-\u03b2 inhibits mitochondrial respiration to suppress IFN-\u03b3 production by human CD4+ T cells. Sci Signal. 2019;12(599):eaav3334. https:\/\/doi.org\/10.1126\/scisignal.aav3334.","DOI":"10.1126\/scisignal.aav3334"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08571-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08571-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08571-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:20:45Z","timestamp":1791336045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08571-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8571"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08571-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy donors, obtained through the Regional Centre for Blood Transfusions at Virgen del Roc\u00edo University Hospital, Sevilla, Spain. Samples were provided anonymously and with written informed consent. All procedures were performed in compliance with institutional guidelines and in accordance with the Declaration of Helsinki. CD19 CAR-T cell samples were obtained from patients treated within the clinical trial EudraCT 2020-003133-38 at the Hematology Department, Hospital Sant Pau (Barcelona, Spain), following appropriate ethical approvals and informed consent. Dual CD19\/CD22 and NKG2D CAR-T cell samples were obtained from patients treated at Hospital Universitario la Paz (Madrid, Spain) under a compassionate use program or the clinical trials NCT06709469 (Dual CD19\/CD22) or NCT06087341 (NKG2D), following appropriate ethical approvals and informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.G.R-L: Honoraria and travel grants from Janssen, Amgen, BMS, GSK, Sanofi, and Stemline Menarini; patent for \u201cCD229-targeting moiety for the treatment of CD229-positive cancer\u201d issued. C.F-dL: Consultancy: BeiGene, Sanofi, GSK, BMS, and Janssen; honoraria: BeiGene, Pfizer, Sanofi, GSK, Takeda, BMS, and Janssen; research funding: Takeda, Amgen, BMS, and Janssen; patent for CD229 CAR-T issued and patent for GPRC5D CAR-T issued. J.A-P-S serves as an advisor or consultant for Novartis, Janssen, Roche, Jazz Pharmaceuticals, Amgen, and Gilead Sciences; has received research funding from Novartis, Janssen, Pfizer, Roche, and Takeda; has received travel support from Roche, Gilead Sciences, and Janssen; and holds patents, royalties, or other intellectual property with Entourage Bioscience related to cannabinoid derivatives. E.G-G has acted as a consultant for Celgene and GLS, and has received travel grants and\/or speaker fees from Celgene, Amgen, and Janssen. E.G-G is also a co-inventor on a patent application filed by the University of W\u00fcrzburg, Germany, and licensed to T-CURX GmbH, Germany (WO2021\/209498 A1), and on other pending CAR T-related patent applications filed by Hospital Universitario Virgen del Roc\u00edo (HUVR) and the University of Seville (US).","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1256"}}